In the beautiful setting of Oxford, Omixon attended the BSHI 2016 meeting. All the key opinion leaders of the British immunogenetics community were present, including Dr. Brendan Clarke from St. James University of Leeds and Professor Derek Middleton from the Royal Liverpool University Hospital, both Omixon Holotype HLA users. Omixon ran a successful lunch symposium where CEO Tim Hague provided updates and future directions of the company. Omixon is very proud to be part of the BSHI community.